Regnante Keith 4

What Happened Keith Regnante, Chief Financial Officer of Keros Therapeutics (KROS), was granted a derivative equity award covering 60,000 shares on February 24, 2026. The transaction is reported as $0.00 at acquisition on the Form 4 (i.e., no cash paid at grant). This is an award/option-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (reporting period: 2026-02-24).
• Amount: 60,000 shares reported as a derivative award; reported acquisition price $0.00 (no cash outlay at grant).
• Shares owned after transaction: not specified in the filing.
• Vesting: footnote states 1/4 vests on Feb 24, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to continued service.
• Filing notes: no indication in the filing of an immediate sale, tax withholding, or a 10b5-1 plan.

Context This type of grant is common executive compensation (time‑based vesting). It does not reflect an immediate purchase or sale; value to the insider depends on future vesting and any exercise price or sale of shares, which the Form 4 does not detail here.